S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Replimune Group Stock Price, News & Analysis (NASDAQ:REPL)

$12.32
+0.61 (+5.21%)
(As of 12/4/2023 ET)
Compare
Today's Range
$11.35
$12.38
50-Day Range
$10.18
$17.11
52-Week Range
$9.79
$29.52
Volume
823,164 shs
Average Volume
623,235 shs
Market Capitalization
$727.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.33

Replimune Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
316.7% Upside
$51.33 Price Target
Short Interest
Healthy
17.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.50mentions of Replimune Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$187,072 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.53) to ($3.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

226th out of 952 stocks

Biological Products, Except Diagnostic Industry

27th out of 155 stocks


REPL stock logo

About Replimune Group Stock (NASDAQ:REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock Price History

REPL Stock News Headlines

Replimune Group (NASDAQ:REPL) Stock Price Down 3.4%
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Replimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Replimune Group Inc REPL
Replimune Group (NASDAQ: REPL)
Arvinas Holding Company (ARVN) Receives a Buy from Barclays
The Latest Analyst Ratings for Replimune Group
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/05/2023
Next Earnings (Estimated)
2/08/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
284
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$51.33
High Stock Price Target
$70.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+316.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-174,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.80 per share

Miscellaneous

Free Float
46,893,000
Market Cap
$727.62 million
Optionable
Not Optionable
Beta
1.45
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Philip Astley-Sparke F.S.A. (Age 52)
    CEO & Director
    Comp: $1.07M
  • Dr. Sushil Patel Ph.D. (Age 52)
    Chief Strategy Officer
    Comp: $665.05k
  • Dr. Robert Coffin Ph.D. (Age 58)
    Founder, President, Chief Research & Development Officer and Director
    Comp: $785.89k
  • Ms. Emily Luisa Hill (Age 43)
    Chief Financial Officer
  • Dr. Colin A. Love Ph.D. (Age 65)
    Chief Operating Officer
    Comp: $419.37k
  • Mr. Andrew Schwendenman (Age 47)
    Chief Accounting Officer & Treasurer
  • Dr. Pamela Esposito Ph.D. (Age 49)
    Chief Business Officer
    Comp: $464.63k
  • Ms. Tanya N. Lewis M.S. (Age 52)
    Chief Development Operations Officer
    Comp: $4.7k
  • Mr. Christopher Sarchi (Age 55)
    Chief Commercial Officer
  • Dr. Konstantinos Xynos M.B.A. (Age 57)
    M.D., Ph.D., Chief Medical Officer














REPL Stock Analysis - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price target for 2024?

6 brokerages have issued 1-year target prices for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they expect the company's share price to reach $51.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL stock has decreased by 54.7% and is now trading at $12.32.
View the best growth stocks for 2023 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.10.

What ETFs hold Replimune Group's stock?

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO),

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.05%), Loomis Sayles & Co. L P (2.19%), FMR LLC (2.15%), Emerald Advisers LLC (1.78%), Emerald Mutual Fund Advisers Trust (1.48%) and Northern Trust Corp (0.77%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:REPL) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -